Clinical Pathology Unit, ASST Fatebenefratelli-Sacco, Milan, Italy.
Department of Biomedical and Clinical Sciences, "Luigi Sacco", University of Milan, Milan, Italy.
Front Immunol. 2022 Mar 18;13:850846. doi: 10.3389/fimmu.2022.850846. eCollection 2022.
A relevant portion of patients with disease caused by the severe acute respiratory syndrome coronavirus 2 (COVID-19) experience negative outcome, and several laboratory tests have been proposed to predict disease severity. Among others, dramatic changes in peripheral blood cells have been described. We developed and validated a laboratory score solely based on blood cell parameters to predict survival in hospitalized COVID-19 patients. We retrospectively analyzed 1,619 blood cell count from 226 consecutively hospitalized COVID-19 patients to select parameters for inclusion in a laboratory score predicting severity of disease and survival. The score was derived from lymphocyte- and granulocyte-associated parameters and validated on a separate cohort of 140 consecutive COVID-19 patients. Using ROC curve analysis, a best cutoff for score of 30.6 was derived, which was associated to an overall 82.0% sensitivity (95% CI: 78-84) and 82.5% specificity (95% CI: 80-84) for detecting outcome. The scoring trend effectively separated survivor and non-survivor groups, starting 2 weeks before the end of the hospitalization period. Patients' score time points were also classified into mild, moderate, severe, and critical according to the symptomatic oxygen therapy administered. Fluctuations of the score should be recorded to highlight a favorable or unfortunate trend of the disease. The predictive score was found to reflect and anticipate the disease gravity, defined by the type of the oxygen support used, giving a proof of its clinical relevance. It offers a fast and reliable tool for supporting clinical decisions and, most important, triage in terms of not only prioritization but also allocation of limited medical resources, especially in the period when therapies are still symptomatic and many are under development. In fact, a prolonged and progressive increase of the score can suggest impaired chances of survival and/or an urgent need for intensive care unit admission.
一部分与严重急性呼吸综合征冠状病毒 2(COVID-19)引起的疾病相关的患者出现不良结局,并且已经提出了几种实验室检测来预测疾病严重程度。其中,外周血细胞的剧烈变化已经被描述。我们开发并验证了一种仅基于血细胞参数的实验室评分,以预测住院 COVID-19 患者的生存情况。我们回顾性分析了 226 例连续住院 COVID-19 患者的 1619 个血细胞计数,以选择纳入预测疾病严重程度和生存的实验室评分的参数。该评分源自淋巴细胞和粒细胞相关参数,并在另外 140 例连续 COVID-19 患者中进行了验证。使用 ROC 曲线分析,得出了最佳截断值为 30.6,该截断值与总体 82.0%的敏感性(95%CI:78-84)和 82.5%的特异性(95%CI:80-84)相关,用于检测结局。评分趋势有效地将幸存者和非幸存者群体分开,早在住院结束前 2 周就开始了。根据给予的症状性氧疗,将患者的评分时间点也分类为轻度、中度、重度和危急。应记录评分的波动,以突出疾病的有利或不利趋势。该预测评分被发现反映并预测了疾病的严重程度,由所使用的氧气支持类型定义,证明了其临床相关性。它提供了一种快速可靠的工具,用于支持临床决策,最重要的是,在治疗仍然是对症的且许多治疗方法正在开发的情况下,在分诊方面不仅是优先级,而且是有限医疗资源的分配。事实上,评分的持续和渐进增加可能表明生存机会受损和/或需要紧急入住重症监护病房。